Thrombosis Journal· 2013Q2

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

Martin H. Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen et al.

553citations
Q2SCImago
2013year

Short summary

Oral rivaroxaban was non-inferior to standard therapy for symptomatic venous thromboembolism (VTE) and significantly reduced major bleeding events (1.0% vs. 1.7%).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Internal Medicine

Internal MedicineMedicine